Chronic Lymphocytic Leukemia Clinical Trial
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter’s Transformation
Summary
The purpose of this study is to evaluate the safety and effectiveness of targeted immunotherapy in combination with ublituximab and umbralisib, in patients with advanced leukemia-cll/" >CLL or Richter's Transformation.
Eligibility Criteria
Inclusion Criteria:
Confirmed diagnosis of B-cell Chronic Lymphocytic Leukemia or Richter's Transformation
Refractory to or relapsed after at least 1 prior treatment regimen
Eastern Cooperative Oncology Group (ECOG) score of 0 to 2
Exclusion Criteria:
Any major surgery, chemotherapy or immunotherapy within the last 14 days
Known hepatitis B virus, hepatitis C virus or HIV infection
Active autoimmune disorder (with the exception of autoimmune hemolytic anemia or ITP)
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 4 Locations for this study
New York New York, 10065, United States
Durham North Carolina, 27710, United States
Philadelphia Pennsylvania, 19104, United States
Seattle Washington, 98109, United States
How clear is this clinincal trial information?
